Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diabetes drugs may fight oral cancer risk

NCT ID NCT05727761

First seen Jan 07, 2026 · Last updated May 18, 2026 · Updated 16 times

Summary

This study tests whether a combination of two diabetes drugs (pioglitazone and metformin) can shrink or improve precancerous patches in the mouth called oral leukoplakia. About 36 adults with high-risk lesions will take the pills twice daily for 12 weeks. The goal is to see if the treatment reduces lesion size and improves tissue health, potentially lowering cancer risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL LEUKOPLAKIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • HealthPartners

    RECRUITING

    Saint Paul, Minnesota, 55130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.